GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab ... non-small cell lung cancer (NSCLC) that has ...

In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...

This trial is looking at dostarlimab by itself and with other immunotherapies ... GSK6097608 is another monoclonal antibody that blocks a protein called CD96 on the cancer cells. Research shows that a ...

Lurie Comprehensive Cancer Center at Northwestern University will participate in a clinical trial testing LIXTE's drug LB-100 in combination with GSK's immunotherapy Dostarlimab for treating ...

for ovarian cancer and a pipeline of other cancer drugs, including PD-1 inhibitor dostarlimab. The NSCLC indication was the biggest hope for the alliance, accounting for almost $600 million of the ...